Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Clorox Co (CLX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Clorox Co vs State Street SPDR S&P Biotech ETF — how do they compare? Clorox Co trades at $106.1 (market cap $13.09B), while State Street SPDR S&P Biotech ETF trades at $159.29. The key difference: Clorox Co pays a 4.62% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Clorox Co nearer its low. Which is the better fit depends on your goals.

CLXXBI
Market Cap
$13.09B
Sector
Consumer StaplesBroad Market / Factor
52-Week High
$127.16$164.28
52-Week Low
$86.12$86.92
Enterprise Value
$18.47B
Dividend Yield
4.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Clorox Co

CLX trades at $106.30, down 1.3% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat estimates with EPS of $1.66, though Q4 2025 missed. The company reported FY2025 revenue of $7.10B and net income of $810M, with improving margins. A dividend increase to $1.25 per share was announced, payable in August 2026.

Outlook is mixed: strong profitability and dividend support value, but high P/E of 22.51 and modest revenue growth pose valuation concerns. Analyst consensus is cautious with a $97.50 price target below current levels. Risks include inflation pressures and competitive threats from private labels, limiting near-term upside potential.

State Street SPDR S&P Biotech ETF

XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.

Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.

Returns comparison

Trailing returns across standard periods

About Clorox Co

With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.

Read more on CLX

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI